RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGY

促进风湿病精准医学发展的资源中心

• 批准号: 10685559
• 负责人: Mary C Nakamura
• 金额: $ 80.74万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-21 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10685559
• 关键词: Acceleration; Address; Area; Automobile Driving; Bioinformatics; Biology; California; Cells; Clinical; Clinical Data; Clinical Informatics; Clinical Research; Clinical Treatment; Collaborations; Computational Biology; Consultations; Data; Databases; Development; Diagnosis; Diagnostic; Disease; Educational workshop; Electronic Health Record; Ensure; Environment; Etiology; Evolution; Funding; Future; Genomics; Goals; Grant; Heterogeneity; Immunology; Immunophenotyping; Individual; Infrastructure; Interdisciplinary Study; Knowledge; Leadership; Mentors; Methodology; Methods; Modality; Molecular; Pathway interactions; Patients; Population; Prognosis; Quality Control; Recording of previous events; Research; Research Design; Research Personnel; Research Project Grants; Resources; Rheumatism; Rheumatology; Running; Sampling; San Francisco; Science; Selection for Treatments; Series; Services; Talents; Technology; Training; Translational Research; Universities; Work; accurate diagnosis; autoimmune rheumatologic disease; clinical care; clinical heterogeneity; clinical phenotype; cohort; data dissemination; data resource; data sharing; design; disorder subtype; genomic data; improved; innovation; interdisciplinary approach; interest; member; molecular phenotype; multiple omics; new technology; next generation; novel; novel therapeutics; precision medicine; programs; research study; single cell sequencing; symposium; transcriptomics; translational scientist; treatment response

PROJECT SUMMARY/ABSTRACT PREMIER, the UCSF Precision Medicine in Rheumatology Center (P30), provides critically important resources and expertise to enable cutting-edge research to advance precision medicine in the rheumatic diseases. PREMIER brings together clinical expertise, defined patient cohorts, state-of-the-art immunophenotyping and genomic technologies with experts in bioinformatics and integrative analyses. This infrastructure facilitates collaborative studies that can integrate the large amounts of clinical and molecular data needed to gain a more fundamental understanding of the biology driving the heterogeneity of clinical phenotypes and treatment responses among individuals with rheumatic disease. PREMIER seeks to lower the barriers to pursuing rheumatology research by providing access to relevant resources along with the expertise to use them appropriately. Our Center includes three Resource Cores that will each provide consultation to guide investigators in study design, analysis, and access to significant expertise and assistance in forming the collaborations needed. The Clinical Data and Informatics Core (CDI), directed by Dr. Jinoos Yazdany, will provide clinical research and informatics services including access to large rheumatic diseases databases, biospecimens and curation of electronic health record data for research discovery; the Genomic Technology Core (GT), co-directed by Drs. Jimmie Ye and Walter Eckalbar, will develop novel genomic technologies and institute specialized workflows and analytic pathways designed for the study of rheumatic diseases; and the Integrative Bioinformatics Core (IB), co-directed by Drs. Marina Sirota and Gabriela Fragiadakis, will address investigator needs for advanced bioinformatics expertise, particularly with regard to single cell analytics, multi-omic integrative analysis, and use of publicly available data. PREMIER’s Administrative Core is led by Dr. Mary Nakamura (Director) and Dr. Jinoos Yazdany (Associate Director) and provides leadership and organizational oversight to the Center. The Core includes a significant enrichment program involving seminars, an annual symposium, workshops led by the Resource Cores, a mentoring program, and a grant program including Development and Feasibility Pilot grants and Core Usage Grants. PREMIER leverages a number of significant UCSF and divisional resources that are highly synergistic with the services offered in PREMIER Resource Cores. Given our track record and deep commitment to innovation, PREMIER is poised to attract new investigators and further advance rheumatology research towards the ultimate goal of improving diagnosis and treatment of rheumatic disease through the detailed elucidation of underlying disease mechanisms.

项目总结/摘要 PREMIER，UCSF精密医学流变学中心（P30），提供至关重要的 资源和专业知识，使尖端研究，以推进精准医学在风湿性关节炎 疾病PREMIER汇集了临床专业知识、定义的患者队列、最先进的 与生物信息学和综合分析方面的专家合作，开展免疫表型分析和基因组技术研究。这 基础设施促进了可以整合大量临床和分子数据的协作研究 需要获得对驱动临床表型异质性的生物学的更基本的理解 以及风湿病患者的治疗反应。总理寻求降低壁垒， 通过提供相关资源沿着使用它们的专业知识来进行流变学研究 适当地。 我们的中心包括三个资源核心，每个资源核心将提供咨询，以指导研究人员进行研究 设计，分析，并获得重要的专业知识和援助，形成所需的合作。的 由Jinoos Yazdany博士指导的临床数据和信息学核心（CDI）将提供临床研究和 信息服务，包括访问大型风湿性疾病数据库、生物标本和 电子健康记录数据的研究发现;基因组技术核心（GT），共同指导博士。 Jimmie Ye和Walter Eckalbar将开发新的基因组技术并建立专门的工作流程 和分析路径设计的风湿性疾病的研究;和综合生物信息学核心 (IB)由Marina Sirota和Gabriela Fragiadakis博士共同指导，将解决研究者对高级 生物信息学专业知识，特别是关于单细胞分析，多组学综合分析和使用 公开可用的数据。总理的行政核心是由博士领导的玛丽中村（主任）和博士。 Jinoos Yazdany（副主任），并为中心提供领导和组织监督。的 核心包括一个重要的充实计划，包括研讨会、年度专题讨论会、 资源核心、指导计划和赠款计划（包括开发和可行性试点赠款） 和核心使用赠款。PREMIER利用了一些重要的UCSF和部门资源， 与PREMIER Resource Cores提供的服务高度协同。 鉴于我们的业绩记录和对创新的坚定承诺，PREMIER准备吸引新的 研究人员和进一步推进流变学研究的最终目标， 通过详细阐明基础疾病诊断和治疗风湿性疾病 机制等

项目成果

Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance.

• DOI: 10.1002/acr.25039
• 发表时间: 2023-01
• 期刊: ARTHRITIS CARE & RESEARCH
• 影响因子: 4.7
• 作者: Ugarte-Gil, Manuel F.;Alarcon, Graciela S.;Seet, Andrea M.;Izadi, Zara;Montgomery, Anna D.;Duarte-Garcia, Ali;Gilbert, Emily L.;Valenzuela-Almada, Maria O.;Wise, Leanna;Sparks, Jeffrey A.;Hsu, Tiffany Y. -T.;D'Silva, Kristin M.;Patel, Naomi J.;Sirotich, Emily;Liew, Jean W.;Hausmann, Jonathan S.;Sufka, Paul;Grainger, Rebecca;Bhana, Suleman;Wallace, Zachary;Jacobsohn, Lindsay;Strangfeld, Anja;Mateus, Elsa F.;Hyrich, Kimme L.;Gossec, Laure;Carmona, Loreto;Lawson-Tovey, Saskia;Kearsley-Fleet, Lianne;Schaefer, Martin;Machado, Pedro M.;Robinson, Philip C.;Gianfrancesco, Milena;Yazdany, Jinoos
• 通讯作者: Yazdany, Jinoos

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.

• DOI: 10.1001/jamanetworkopen.2021.29639
• 发表时间: 2021-10-01
• 期刊: JAMA network open
• 影响因子: 13.8
• 作者: Izadi Z;Brenner EJ;Mahil SK;Dand N;Yiu ZZN;Yates M;Ungaro RC;Zhang X;Agrawal M;Colombel JF;Gianfrancesco MA;Hyrich KL;Strangfeld A;Carmona L;Mateus EF;Lawson-Tovey S;Klingberg E;Cuomo G;Caprioli M;Cruz-Machado AR;Mazeda Pereira AC;Hasseli R;Pfeil A;Lorenz HM;Hoyer BF;Trupin L;Rush S;Katz P;Schmajuk G;Jacobsohn L;Seet AM;Al Emadi S;Wise L;Gilbert EL;Duarte-García A;Valenzuela-Almada MO;Isnardi CA;Quintana R;Soriano ER;Hsu TY;D'Silva KM;Sparks JA;Patel NJ;Xavier RM;Marques CDL;Kakehasi AM;Flipo RM;Claudepierre P;Cantagrel A;Goupille P;Wallace ZS;Bhana S;Costello W;Grainger R;Hausmann JS;Liew JW;Sirotich E;Sufka P;Robinson PC;Machado PM;Griffiths CEM;Barker JN;Smith CH;Yazdany J;Kappelman MD;Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc;Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA)
• 通讯作者: Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA)

The racial/ethnic and sociocultural aspects of the pandemic in rheumatology.

• DOI: 10.1016/j.berh.2021.101665
• 发表时间: 2021-03
• 期刊: Best practice & research. Clinical rheumatology
• 作者: Taylor T;Yazdany J;Gianfrancesco MA
• 通讯作者: Gianfrancesco MA

Personalizing routine lab tests with machine learning.

通过机器学习个性化常规实验室测试。

• DOI: 10.1038/s41591-021-01486-4
• 发表时间: 2021
• 期刊: Nature medicine
• 影响因子: 82.9
• 作者: Tang,Alice;Oskotsky,Tomiko;Sirota,Marina
• 通讯作者: Sirota,Marina

Increased alloreactive and autoreactive antihuman leucocyte antigen antibodies associated with systemic lupus erythematosus and rheumatoid arthritis.

• DOI: 10.1136/lupus-2018-000278
• 发表时间: 2018
• 期刊: Lupus science & medicine
• 影响因子: 3.9
• 作者: Jackman RP;Cruz GI;Nititham J;Triulzi DJ;Barcellos LF;Criswell LA;Norris PJ;Busch MP
• 通讯作者: Busch MP